All posts by vcbridge.com

China Natural Resources Receives Nasdaq Notification Regarding Minimum Bid Requirements

HONG KONG, July 11, 2024 — On July 5, 2024, China Natural Resources, Inc. (NASDAQ: CHNR) (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common shares was below the minimum of $1.00 per share for a period of 30 consecutive business days. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company’s common shares, which will continue to trade uninterrupted on Nasdaq under the ticker “CHNR”.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until January 2, 2025 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company’s common shares is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance with the minimum bid price requirement by January 2, 2025, the Company may be eligible for an additional 180-calendar-day grace period.

About China Natural Resources:

China Natural Resources, Inc., a British Virgin Islands corporation, through its operating subsidiaries in the People’s Republic of China (the “PRC”), is currently engaged in the exploration for lead, silver and other metals in the Inner Mongolia Autonomous Region of the PRC and is actively exploring further business opportunities in the natural resources sector and other sectors.

SOURCE China Natural Resources, Inc.


ProofPilot Announces Series C Funding

NEW YORK, July 11, 2024 — ProofPilot, a leading Clinical Experience Platform (CXP), announced the closing of its Series C financing, led by Sopris Capital with Mitsui & Co. (U.S.A.), Inc. participating.

“Much of the focus in clinical trial technology has been on data capture and AI, but supporting the clinical trial experience for stakeholders has taken a backseat,” said Chris Venezia, CEO of ProofPilot. “Our strategic advisory board, comprising patients, research sites, and sponsors, is solving the right challenges and needs to modernize experiences for all stakeholders. This repeat investment from our Series B investors recognizes the market’s need and provides us with resources to scale and accelerate life-saving therapies.”

ProofPilot’s platform, StudyCoPilot, centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. The products and services support key initiatives like improving DE&I, streamlining recruitment & retention, and easing site burden. ProofPilot has scaled its capabilities for enterprise use and has industry leading pharmaceutical clients deploying StudyCoPilot globally.

“The sky is the limit with ProofPilot, and we are excited about investing in the company. We have tremendous confidence in the team and are proud to see some of the world’s leading life sciences companies adopt the technology,” said Abinav Sankar, Partner at Sopris Capital.

About ProofPilot

ProofPilot enhances clinical trials with its Clinical Experience Platform (CXP). The StudyCoPilot platform centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. Learn more at: https://www.proofpilot.com.

About Sopris Capital

Sopris Capital invests growth equity in technology-enabled business services and SaaS companies solving critical pain points. Sopris partners with fast-growing companies with a validated business model, proven product/market fit, and a strong management team. Learn more at: http://www.sopriscapital.com.

About Mitsui

Mitsui & Co. (U.S.A.), Inc. (“Mitsui USA“), a subsidiary of Mitsui & Co., Ltd., Tokyo, Japan, is one of the most diversified trading, investment, and service enterprises globally. Mitsui & Co. pursues “360° business innovation” across product sales, logistics, financing, and major international infrastructure projects. More information on Mitsui USA can be found at www.mitsui.com/us.

Media Contacts: Colleen Yang, [email protected]

SOURCE ProofPilot


Element Biosciences Raises Over $277 Million to Develop and Commercialize Differentiated Products and Continue Rapid Growth

SAN DIEGO, July 11, 2024 — Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced over $277 million in Series D investment to support its growing global customer base with disruptive DNA sequencing and multi-omics technologies for years to come. The oversubscribed round was led by Wellington Management with participation from new and existing investors, including Samsung Electronics, Fidelity, Foresite Capital, funds and accounts advised by T. Rowe Price Associates, Inc, and Venrock, among others. This brings Element’s cumulative raise to over $680 million.

“After years of watching Element’s impressive progress from the sidelines, we are excited to support the company’s next chapter of growth and development,” said Joshua Sommerfeld, healthcare sector lead at Wellington Management Private Investing. “Their platform combines quality, cost, and flexibility advantages that disrupt the incumbent price curve. By bringing end-to-end integrated multi-omic workflows onto a single system, Element has potential to accelerate biological discovery.”

“Molly and the team at Element are cementing their position in a highly competitive environment,” said Mr. Jong-Hee (JH) Han, Vice Chairman and CEO at Samsung Electronics. “Their products set a new industry standard and are foundational to the next wave of biological innovation that will help researchers and businesses around the globe deliver on the promises of precision medicine and artificial intelligence. We are incredibly excited about Element’s vision to make precision medicine affordable and are impressed with the team they built together.”

This funding will further support the commercialization of AVITI™, Element’s benchtop DNA sequencer, and bolster the upcoming launch of AVITI24™, the first instrument to combine state-of-the-art sequencing and cyto-profiling (mapping cell characteristics) into a single integrated biology platform. AVITI24 revolutionizes research by enabling simultaneous examination of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells – empowering researchers to gain unparalleled insights into biological systems with unprecedented ease.

“After a decade of an 800-pound gorilla dominating the ecosystem, it has been a privilege to help the exceptional Element team deliver customer-centric products that advance the quality, affordability and democratization of genomic analysis,” said Bryan Roberts, Partner at Venrock and an early investor in Element, alongside Jim Tananbaum at Foresite Capital.

“We cofounded Element based on a simple belief that cutting-edge science should be available to the entire research community. Element has taken the first step to democratize sequencing and will continue helping the community uncover the secrets of biology with high-quality, flexible, rapidly iterative, and affordable tools that are accessible to more scientists.” said Molly He Ph.D., CEO, Element Biosciences. “Element has grown an increasingly large, enthusiastic, and loyal customer base thanks to our innovative products and a collaborative, tenacious team that has remained committed to Element’s mission. An oversubscribed round against the backdrop of a challenging macroeconomic environment is a testament to our mission. With the support of our new and existing investors, Element is solidifying its future as the next name-brand biological tools company – a true unicorn.”

In the last 12 months, Element’s install base of AVITI has grown from approximately 40 units to more than 190. Element’s customers span a diverse set of industries including academia, biotech, cancer research, and agricultural science in more than 25 countries, and its technologies are used by pioneering organizations like Cerba Research, Cornell University, Garvan Institute, Revvity, Stowers Institute, VIB, and others.

The University of Minnesota Genomics Center (UMGC), which installed its first AVITI in mid 2023, has purchased four additional AVITIs over the past year. Dr. Kenny Beckman, Director of the UMGC, has been pleased with its performance. “The AVITI is simple to operate, easy to integrate from a data perspective, and the quality of the output is higher than with our legacy NGS instruments,” said Dr. Beckman. “The AVITI’s scale is a great fit for our clients, most of whom need both fast turnaround and low cost.”

“Precision medicine’s vast potential is being unlocked by cutting-edge genomic and multiomic technologies. Element’s groundbreaking sequencing is driving significant advancements in precision diagnostics research across critical disease areas,” said Thomas P. Slavin, Chief Scientific Officer at HALO Precision Diagnostics, which installed four AVITI sequencers over alternative high-throughput offerings from an NGS competitor in 2023.

Reflecting on Element’s journey, Molly added, “We simply wouldn’t have made it to this remarkable stage without the initial pioneers and risk-takers who formed our earliest customer base. Element is especially grateful for their support.”

About Element Biosciences, Inc.
Element Biosciences is a pioneering life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. We are focused on developing disruptive DNA sequencing and multi-omics technology for research markets. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook.

Media Contact
[email protected] 

SOURCE Element Biosciences


HUI obtiene un compromiso de capital de 25 millones de euros de Nimbus Capital

PESCARA, Italia, 11 de julio de 2024 — HUI se complace en anunciar el cierre de un compromiso de capital social de 25 millones de euros de Nimbus Capital, un fondo con sede en Panamá. Esta inversión impulsará aún más el crecimiento de HUI como la súper aplicación VC 3.0, utilizada por miles de emprendedores, nuevas empresas e inversores por sus características únicas en el mercado.

“HUI es una súper aplicación única, con una base de código impresionante de más de 1,2 millones de líneas de código, más de 20 aplicaciones que cubren todas las funciones y procesos comerciales, desde ventas hasta recursos humanos, recaudación de fondos, gestión de proyectos, inteligencia y financiación colectiva, todo en una sola No requiere conocimientos de codificación para operar a través de API con servicios externos, diseñados específicamente para cada actor en la escena global de VC”, explicó Luigi Valerio Rinaldi, fundador de HUI y presidente de Enry’s Island SpA.

El enfoque basado en datos de HUI lo distingue de agregadores como Crunchbase, DealRoom y PitchBook. A diferencia de estas plataformas, HUI no depende de rastreadores para obtener datos. En cambio, cuenta con una base de datos y un modelo de datos completos, con funcionalidades de IA que se están desarrollando para ofrecer un valor significativo en recomendaciones y predicciones.

“El enfoque basado en datos y las próximas características de blockchain e IA programadas para el tercer trimestre nos obligaron a invertir en HUI”, afirmó Robert J. Baker, socio director de Nimbus Capital. “Nimbus se dedica a identificar futuros unicornios y abordar las necesidades avanzadas del panorama global de capital de riesgo. HUI se alinea perfectamente con nuestra visión”.

El compromiso de capital de 25 millones de euros forma parte del plan de tracción de HUI, tras una ronda inicial de 300.000 euros y una asociación comercial con uno de los integradores de sistemas de TI internacionales más reconocidos. Con un número cada vez mayor de ecosistemas de VC que adoptan HUI, y en preparación para cotizar en una Bolsa de Valores Europea, con el respaldo de una importante firma consultora, HUI aspira a ser la primera plataforma VC 3.0 todo en uno que cotiza en bolsa del mundo.

Esta inversión acelerará significativamente la estrategia de producto de HUI, mejorando su uso de IA, Blockchain y funciones 3.0 como Metaverse y Gaming. HUI también ampliará sus actividades de marketing y ventas en los mercados de EE. UU., Latinoamérica, África y el Lejano Oriente.

El compromiso de capital también incorpora a Luigi V. Rinaldi como socio de riesgo en Nimbus, aprovechando sus 20 años de experiencia en capital de riesgo para mejorar el liderazgo financiero y tecnológico de Nimbus.

“Estoy encantado con la profunda armonía y la visión compartida con Nimbus y su fundador, Robert. Esta asociación tendrá un impacto significativo en la escena global de VC”, añadió Luigi Valerio Rinaldi.

Foto: https://mma.prnewswire.com/media/2458456/HUI_Equity_Commitment_Nimbus_Capital.jpg
Logo: https://mma.prnewswire.com/media/2458455/HUI_Logo.jpg

Contacto de medios: 
Equipo de Relaciones con Inversores 
+39 3939774542
[email protected] 


SusHi Tech Tokyo 2024 Global Startup Program spotlights a positive future for the startup ecosystem in Tokyo with a record-breaking 40,000+ attendees over two days

SAN FRANCISCO, July 10, 2024 — Amidst the challenging wider economic landscape, the Tokyo Metropolitan Government (TMG) today announced a successful conclusion to the SusHi Tech Tokyo 2024 Global Startup Program, which was held on May 15-16, 2024.

  • Asia’s largest global innovation conference, welcomed an unprecedented number of startups and participants across the global, bringing over 40,206 participants – highlighting the bright future of the startup ecosystem in Japan.

Numbers at a glance

Over 40,206 attendees took part in this year’s event, seeing a year-over-year increase of over 50% with just over 26,000 attendees in the 2023 edition. The visitors come from a mix of 430+ startups; 82 countries and 321 cities; and 424 startup booths. Most importantly, the event successfully facilitated 3,169 business matches. 

Final Results of the SusHi Tech Challenge 2024

One of the key highlights in the event was the SusHi Tech Challenge 2024, a pitch contest by the world’s leading startups to determine the number 1 sustainable high city technology that will bring sustainable cities into a reality.

507 startups from 43 markets competed, and 7 startups made it to the final round including Entomal Biotech Sdn Bhd (Malaysia), Cool Innovation, Inc (Japan), BUYO Bioplastics Company Limited (Vietnam), Fermenstation Co.,Ltd (Japan), CancerFree Biotech (Taiwan), E-Port Pte. Ltd. (Singapore) and Degas Ltd. (Japan).

Taking home the grand prize of 10 million yen was Fermenstation Co.,Ltd., who was also awarded several special prizes by Sumitomo Realty & Development Co., Ltd, Tokyo Kiraboshi Financial Group, Inc, Tokyo Tatemono Co., Ltd, Mitsubishi Estate Residence Co., Ltd., and Mori Building Co., Ltd.

Other special prize winners include:

  • CancerFree Biotech, awarded by Shimizu Coporation
  • Entomal Biotech Sdn Bhd, awarded by Global Digital Innovation Network
  • BUYO Bioplastics Company Limited, awarded by Mitsui Fudosan Co., Ltd.
  • Cool Innovation, Inc, awarded by Chuo-Nittochi group Co., Ltd.
  • Degas Ltd., awarded by Pocketalk Corp
  • Tokyo Governor Yuriko Koike addressed the participants at the closing ceremony of the event, “These two days of the SusHi Tech Tokyo 2024 Global Startup Program were bustling with energy and excitement. We also newly established the SusHi Tech Award to recognize outstanding startups. I am confident that the seeds of open innovation have been sown through the various encounters and interactions that took place here today. I hope all of you will cherish the connections you have made here, and continue to bring about great innovation. Next year’s event will be held from May 8th to the 9th, here at Tokyo Big Sight. “Come to Tokyo every May” —those words will be what keep us connected. I look forward to seeing you again next year, during the favorable season in Tokyo.”

Please access here for more information.

About Global Startup Program

TMG’s “Global Innovation with STARTUP” has been active since November 2022. The program strategy called “10×10×10 Innovation Vision” focuses on increasing the number of 1. Unicorn companies from Tokyo, 2. Startup companies from Tokyo, and 3. Public and Private Startups from Tokyo by ten times over the next 5 years. On February 2023, TMG held the “City-Tech.Tokyo” at the Tokyo International Forum which was Japan’s largest global startup event with 26,000 visitors in two days. This year, TMG levels up further with SusHi Tech Tokyo 2024 as Asia’s largest global startup event including contents such as speaking sessions, a pitch contest and exhibits.


Adona Medical, a Shifamed Portfolio Company, Raises $33.5 Million in Series C Financing

Funding to support next stage of product development and early clinical experience of company’s novel interatrial shunt and remote monitoring solution for patients with heart failure

LOS GATOS, Calif., July 10, 2024 — Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today it has secured $33.5 million in Series C financing. The funds will be used to further product development and to initiate clinical use of the company’s adjustable interatrial shunt with integrated bi-atrial pressure monitoring. The financing was led by Cormorant Asset Management and TCP Health Ventures, with participation from Excelestar Ventures, the PA MedTech VC Fund II, Unorthodox Ventures, AMED Ventures, and other new and existing investors.

“Heart failure is a complex condition that benefits from an individualized treatment paradigm, yet many of the device-based treatment options available today offer a one-size-fits-all approach,” said Paul Sorajja, MD, Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center, Minneapolis Heart Institute Foundation. “Adona’s innovative shunt and sensor pairing aims to provide a more individualized management strategy and is designed so that shunt flow can be adjusted to best suit the needs of each individual patient, both initially and as their condition evolves over time. I look forward to working with the Adona team as they move into clinical use later this year.”

“Despite advancements in heart failure therapies, challenges remain that limit patient applicability and physician adoption with first-generation devices,” said Bihua Chen, Founder and Managing Member of Cormorant Asset Management. “We are pleased to lead this round as we believe Adona’s technology has the potential to disrupt the field and benefit the millions of patients suffering from heart failure.”

The Adona device includes a shunt that features a flow channel with an adaptable geometry that can be made larger or smaller post-implantation via the use of a proprietary induction catheter. In addition, the implantable device features integrated sensors designed to capture pressure readings from both the left and right atria multiple times per day without requiring patient interaction. These daily readings can provide physicians with a more complete understanding of a patient’s hemodynamic status and can augment shunt therapy by enabling more informed medical management. Heart failure is a progressive condition that impacts approximately 6.5 million patients in the United States and as many as 26 million patients globally.1

“Adona is committed to improving outcomes for patients with heart failure. We’ve developed multiple innovative technologies that we believe will elevate the impact that is achievable with device-based interventions,” commented Brian Fahey, Co-Founder and Chief Executive Officer of Adona Medical. “The team has made tremendous progress in advancing our solution for heart failure management and we are grateful for the strong ongoing support from our investors as we take the next steps in our journey.”

About Adona Medical, Inc.
Adona Medical, a privately held portfolio company of Shifamed, LLC, is a pre-clinical stage medical technology company developing next-generation interatrial shunting and remote patient monitoring solutions for patients with advanced heart failure. The Adona Medical heart failure management platform is an investigational device and is not approved for use in the U.S. or anywhere in the world. To learn more, please visit www.adonamed.com.

About Shifamed, LLC
Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that forge a path toward a world where patients are able to lead longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.

MEDIA CONTACT:
Jennie Kim
SPRIG Consulting, LLC
[email protected]

References:

  1. Benjamin et al. Circulation 2018.

SOURCE Adona Medical


X-Bow Raises More Than $70 Million Series B to Accelerate Expansion of Hypersonic and Solid Rocket Motor Technologies

ALBUQUERQUE, N.M., July 10, 2024 — X-Bow Systems Inc. (X-Bow), the nation’s leading non-traditional producer of advanced manufactured solid rocket motors (SRMs) and hypersonics technologies, today announced the successful completion of the initial close of its Series B financing, raising over $70 million. This private capital will accelerate the rapid growth of its hypersonic-capable vehicles, strategic and tactical scale solid rocket motor programs, and completion of its Luling, TX gigafactory campus. The company will also be expanding its engineering and R&D facilities across New Mexico. The round was led by National Security technology-focused growth equity firm Razor’s Edge, with additional participation from Lockheed Martin Ventures, Boeing Ventures, Crosslink Capital and Balerion Space Ventures.

“Razor’s Edge invests in companies with great leadership teams and differentiated products that solve large, difficult National Security challenges, including defense and space needs. The Ukraine conflict has exposed the significant gaps that exist in the SRM industrial base. X-Bow’s team identified these critical gaps well ahead of the conflict and has built a sizable lead over other emerging suppliers. The company’s proprietary manufacturing technologies and insights into the market have enabled it to build a broad suite of SRM and energetics products. X-Bow has successfully demonstrated the ability to apply and scale these products to address huge needs in affordable hypersonics and the broader SRM industrial base and this capital will enable the company to make an even more meaningful impact in National Security,” said Mark Spoto, co-founder and Managing Partner at Razor’s Edge and an X-Bow Board Member.

With this funding now secured, X-Bow will accelerate its growth trajectory as the nation’s third supplier of Solid Rocket Motors and continue in its quest to rapidly innovate and deliver agile, affordable solutions for SRMs, hypersonics and associated adjacent markets. 

“X-Bow Systems has experienced significant growth and success in the past year, securing multiple contracts for SRMs, energetics and launch services.  These successes are directly attributable to our team’s expertise and our patented advanced manufacturing techniques, which allow us to build, scale and produce SRMs and energetics more affordably than traditional methods. The Series B funding will augment growth by accelerating the completion of the country’s second largest SRM production facility (by capacity) in Luling, TX.  This expansion addresses both critical industrial base and defense needs, and we’re grateful for the support of our investors and various industrial partners,” stated Jason Hundley, CEO and Founder.

Union Square Advisors LLC served as exclusive financial advisor to X-Bow for this financing transaction. 

ABOUT X-BOW SYSTEMS
X-Bow Systems is disrupting the aerospace and defense industry with innovative and cost-effective advanced manufactured energetics for the solid rocket motor and launch vehicle market. X-Bow is also designing and building a suite of modular, strategic and tactical scale solid rocket motors and small launch vehicles for both orbital and suborbital launch services. X-Bow is led by CEO Jason Hundley, Chairman Mark Kaufman, CTO Max Vozoff, CRO Maureen Gannon, General Counsel John Leary and a growing team of seasoned industry veterans and new space entrepreneurs. X-Bow is a dual-use technology company with headquarters in Albuquerque, New Mexico, significant production facilities in Texas, and additional presence in California, Alabama, Utah, Colorado and Washington, DC.

SOURCE X-Bow Systems


CCV Capital’s Wei Zhou: AI Winter Coming in Second Half of Year, Remaining Genuine as Fake Ones Eliminated, Silicon Valley Startups Only Need to Survive to Next Cycle

SANTA CLARA, Calif., July 10, 2024 — “It’s very popular for Silicon Valley startups nowadays to say they only need to survive until the next cycle,” said Wei Zhou, who witnessed multiple cycles in venture capital industry, from his time at KPCB to now as Founding Managing Partner of CCV Capital.

This year, the primary market remains bleak, many VCs are facing the fundamental problem of capital shortage. However, Wei emphasized that in the entire VC investment field, AI is undoubtedly the direction where all investment institutions have invested the most and largest amounts this year, both in terms of number of deals and dollar amount.

In addition to “hot” this year, many “pseudo-entrepreneurs” and “pseudo-demands” have also emerged. Having witnessed the ups and downs of cutting-edge technology venture capital industry over the years, Wei realized: the AI winter is imminent.

“I predict that AI will cool down starting from the third quarter of the second half of this year, and remain cold until the second half of next year.”

Wei recalled the now classic case of Shukun Technology. The years 2015-2017 were when AI medical imaging applications in China were at their hottest. Many companies received huge financing. However, after 2017 the enthusiasm cooled sharply. Due to the previously overvalued AI imaging companies unable to generate revenue, the primary market remained cold from 2017 until early 2019.

“Nothing can grow in the winter cold, but it will also retain some particularly robust seedlings. So when winter passes, these few remaining seedlings will grow very fast. The business environment has also improved, the products are more mature, and meanwhile the competition has reduced.” 

Always daring to invest in cold sectors, Wei seized the timing in 2018 when AI medical imaging was at its coldest, and led Shukun Technology’s US$200 million Series A+ round. At that time, he judged that China’s AI medical imaging industry was ready, the technology was mature enough, and commercialization was the only thing lacking.

As represented by Shukun Technology, after 2019, the business environment and real application scenarios of AI imaging companies began to emerge. Sure enough, a number of companies that survived the winter saw their revenues rise.

The once wildly popular metaverse concept also basically fits this cyclic curve.

“It was hot for a year and a half before cooling, and still hasn’t warmed up,” he predicts that AI will follow the same pattern to cool for a year or year and a half. “So we’re not worried about AI. It’s very popular nowadays in Silicon Valley for startups to say they only need to survive until the next cycle.”

In Wei’s words, although everyone knew from the beginning that AI was a great direction, exactly where and how to land commercial applications was still unclear to all.

This reminds him of 2000 when everyone was investing in the Internet. Looking back, everyone now certainly knows the best entrepreneurial direction at that time was portal sites. But if you went into e-commerce and other sectors that rose later at that time, because the overall environment did not match and the market was not yet ready, it actually could not take off.

Wei bluntly said, AI entrepreneurs today also face the problem of timing. 

“Choosing what to do at this point in time is most appropriate. You may have great vision, but if you’re too early and the surrounding environment is not ready, that can be terrifying.”

In Wei’s view, AI is still just at the beginning application stage, and too many people are trying in different directions, but over the past year and a half, the overall AI environment has gradually shown some of the industry disorders of the cryptocurrency field back then.

“It became too hot, and many of those who rushed in were not thinking about how to use AI to solve actual existing problems, but were using various concepts to speculate. We call these pseudo-entrepreneurs, people chasing waves.”

From March last year to February this year when Sora came out, AIGC instantly became a star that sparked public enthusiasm around the tech arena.

Text-to-image, text-to-video, image-to-video, seem to have become buzzwords in the AI circle. 

Wei bluntly said, “Some money was invested in places where it was wasted.”

The current AIGC direction is like Internet startups back then. Take online stores for example, anyone who understands the basics of the Internet can participate. 

“Hard to say if you can win, but you can play in it.”

In his opinion, the current entrepreneurial environment in the AIGC field is similar.

“Basically, if you understand AI, just like Internet startups back then, as long as you notice some market demand, you can dive in to do it. You can enter just with your so-called ordinary business sense.”

He emphasized that generative AI technology is crucial, but “without differentiated technology far surpassing others, achieving technological monopoly, it will eventually become a so-called mass consumer product – every site will have it, everyone uses different vendors, the products won’t differ too much.” If this continues, companies with high value will be very few, “there will be a large batch of barely surviving companies.”

Under such circumstances, Wei believes it will be great if AI cools down in the second half of this year. “It will eliminate some so-called pseudo-entrepreneurs and pseudo-demands, making the environment cleaner. Some very solid entrepreneurs who are using technology to solve real problems will succeed.” 

Specifically, he believes that B2B applications that can influence industry cost structures and entire industry workflows are truly valuable AI applications. “For B2B, if your understanding of the industry is superficial, you can’t even get your foot in the door.” He analogized such applications to the “shield machines” used to build highways. 

But B2B applications also have higher requirements for founding teams.

Not only must they have sufficient understanding of the AI industry and progress, they also need to know the roles of each participant in the workflow, and be able to combine their own AI products with the entire workflow to produce a “shortcut effect”.

“They can sensitively feel which part of the costs the AI application can chop out of the workflow – not reducing, but making the participating side that previously took a big piece of the pie disappear, then your value is huge.”

In the interview, Wei mentioned Huski.ai, a Silicon Valley B2B startup he invested in. Huski.ai mainly provides cost-effective solutions for IP lawyers and their staff to help them review, monitor and enforce trademarks for clients.

Wei said law firms previously handled at most 10 cases a year, because the economic and manpower costs of evidence collection for law firms and brands to deter counterfeiters were very high. After Huski.ai intervened with AI, evidence collection costs were infinitely reduced, even directly replacing the evidence collection process, no longer subject to manpower constraints.

For entrepreneurs, Wei introduced three advantages of B2B entrepreneurial directions to Sohu Science and Technology. First, there are currently fewer teams with cross-border capabilities, so competition is relatively less fierce. Second, revenue comes relatively fast. Third, it can cause thorough changes to an industry.

Therefore, Wei frankly said that after investing in large model and platform companies, he now prefers “companies that cut very deep into a vertical field”.

Chinese AI companies cannot afford to expand globally only after becoming big, otherwise they will be “rolled to death” domestically, Wei said.

Although from the perspective of the AI field, he currently believes it has not reached the point of “unable to survive without going global”. But he emphasized, “Competition among Chinese companies domestically is extremely fierce, like the dark forest in The Three Body Problem. In the age of deglobalization, Chinese companies must still adhere to globalization.” 

“From day one, Chinese AI companies must consider and prepare in advance. Not like before, first growing big domestically then expanding globally. By then you will encounter a lot of obstacles and guard mentality. That is to say, from day one, as long as you have sufficient confidence and resources, begin implementation in parallel.”

For entrepreneurs, he advised focusing on future global target markets early on in the initial stages, establishing localized teams from partners to services with a “local image” in the home countries. 

“But you actually have close ties with Chinese companies and supply chains.” That is to say, while fully integrating with local markets, culture, regulations and so on to build a localized image, also maintain connections with China in resources, talent, supply chain and technology to form a distributed structure. “Becoming like many mushrooms sprouting simultaneously from different places, but with a certain degree of mutual support between them.”

Wei emphasized looking for investments to support Chinese innovation when making investment decisions. “In the past, 15-20% of our projects were overseas, certainly mostly related to China, either the founders were Chinese, or linking closely with China’s supply chain and market or talent.”

Wei pointed out that if a company can obtain sufficiently unique data in a vertical field to train models, it can create barriers. Take Shukun Technology as an example. After years of R&D and exploration, Subtle Medical used its unique medical data to self-research and train the multimodal medical model ShuKunGPT. 

In addition, if you can understand and grasp an industry deeply enough, you can also form leading advantages and barriers. In such vertical scenarios, “others can hardly catch up with you overnight, even if you have a lot of money, this is still an advantage.”

In summary, have to focus on subdivided industries. Once relatively unique vertical opportunities are identified, quickly build closed data loops. 

“In any event, I feel like under today’s environment, if entrepreneurs want to avoid the situation of ‘nothing grows under huge trees’, they still have to think clearly – exactly what is the direction and advantage of my startup.”

SOURCE CCV Capital


DAS LITAUISCHE DROHNEN-STARTUP GRANTA AUTONOMY STARTET MIT EINER 1-MILLIONEN-EURO-STARTKAPITALRUNDE DURCH

Die kampferprobte Überwachungstechnologie des Unternehmens wird die Art und Weise, wie Streitkräfte komplizierte und multidisziplinäre Aufklärungsmissionen bewältigen, verändern

VILNIUS, Litauen, 10. Juli 2024 — Granta Autonomy, ein innovatives Startup-Unternehmen, das sich auf vollautonome UAVs für Nachrichten-, Überwachungs- und Aufklärungsmissionen spezialisiert hat, gab heute den erfolgreichen Abschluss seiner Seed-Finanzierungsrunde in Höhe von 1 Million Euro bekannt. ScaleWolf VC, der führende litauische VC-Fonds und Accelerator für Technologien mit doppeltem Verwendungszweck, leitete die Runde mit Beteiligung von Brolis Defence und HFL Holdings. Das neue Kapital wird Granta Autonomy in die Lage versetzen, die Entwicklung und Produktion seiner hochmodernen leichten Überwachungs- und Aufklärungsdrohnen, Mikrokardans und digitalen Datalink-Software zu beschleunigen, die das Team persönlich an der ukrainischen Front getestet hat.

Granta Autonomy entwickelt seit 2015 ferngesteuerte Aufklärungsdrohnen, leichte Gimbals und die einzigartige Datalink-Software. Das von den ehemaligen Militäringenieuren Gediminas Guoba und Laurynas Litvinas gegründete Unternehmen beliefert heute die NATO-Streitkräfte in ganz Europa mit seiner Palette handgestützter Hornet-Drohnen und bietet darüber hinaus einer Reihe von Partnern seine firmeneigenen, äußerst zuverlässigen und leichten Mikrokardanringe an, die die leichtesten direkt angetriebenen Kardanringe auf dem Markt sind. Die Micro Gimbals von Granta Autonomy sind mit einem leistungsstarken Kamerasystem ausgestattet, das eine klare Bildaufnahme bei Tag über große Entfernungen (bis zu 5 km) ermöglicht und eine wichtige thermische Sicht für Nachteinsätze bietet, um den Erfolg der Missionen rund um die Uhr sicherzustellen.

„Die traditionelle Kampfzone entwickelt sich weiter, und die westlichen Armeen benötigen robuste, zuverlässige und flexible Lösungen. Granta Autonomy ist bestrebt, sicherzustellen, dass unsere Systeme in Europa hergestellt werden können, um die Abhängigkeit von externen Quellen zu verringern. Die heutige Finanzierung ermöglicht es uns, unsere Produktionskapazitäten zu erhöhen, um die in Europa benötigten Großanwendungen bereitzustellen”, sagte Gediminas Guoba, Gründer und Geschäftsführer von Granta Autonomy. „Unser Team arbeitet direkt mit den Soldaten in der Kampfzone zusammen, testet unsere Produkte und Software in Kampfgebieten und arbeitet gemeinsam an Lösungen, die sich auch unter schwierigsten Bedingungen bewähren. Diese von unseren westlichen Partnern geschätzte Erfahrung in der Kampfzone ist die Grundlage für unsere Mission, die Drohnenaufklärung für die Streitkräfte weltweit zu revolutionieren.”

Die neueste Drohne von Granta Autonomy, die Hornet XR, ist eine kleine, schwer zu entdeckende, von Hand zu startende Mini-Aufklärungsdrohne mit mehreren entscheidenden Merkmalen für verdeckte Missionen. Mit einem einfachen Wurfstart und einer geräuschlosen Flugdauer von bis zu 3 Stunden kann sie große Entfernungen (bis zu 160 km) unbemerkt zurücklegen. Vorprogrammierte Missionen gewährleisten einen autonomen Betrieb, selbst bei Funkstille oder in Umgebungen, in denen kein GNSS verfügbar ist. Das ultraleichte Flugzeug landet selbständig im Tiefstflugverfahren, sodass es auch auf engstem Raum leicht zu bergen ist, und sein kompaktes, modulares Design ermöglicht den bequemen Transport im Kofferraum eines Autos.

Die leistungsstarken, aber leichten GS-214X- und GS-218X-Mikrokardansysteme von Granta Autonomy ermöglichen es Hornets und anderen Drohnen von Drittanbietern, tagsüber scharfe Bilder aus großen Entfernungen (bis zu 5 km) aufzunehmen, und enthalten eine Wärmekamera für Einsätze bei Nacht. Die Digital Datalink Software von Granta Autonomy stellt sicher, dass der Gimbal mit den meisten Bodenkontrollstationen (GCS) kompatibel ist.

Guoba fügt hinzu: „Die Hornet XR ist ein Beispiel für unsere Konstruktionsphilosophie, die auf dem Fachwissen unserer militärischen UAV-Betreiber und -Ingenieure beruht. Sie bietet branchenweit führende Flugzeiten, einfache Bedienung und robuste Haltbarkeit, was zu größerer Effizienz, niedrigeren Kosten und unerreichter Zuverlässigkeit bei komplexen, multidisziplinären Missionen führt. Das Gleiche gilt für unsere Mikro-Kardanringe; als wir anfingen, gab es keine Kardanringe für kleine Drohnen wie die unseren auf dem Markt; jetzt produzieren wir die leichtesten direkt angetriebenen Kardanringe auf dem Markt.”

Edvinas Kerza, geschäftsführender Gesellschafter von ScaleWolf VC und ehemaliger Vizeminister des litauischen Verteidigungsministeriums, fügt hinzu: „Seit wir Gediminas und das Team kennengelernt haben, sind wir von der bahnbrechenden Technologie und der Vision des Granta Autonomy Teams beeindruckt. Ihr innovativer Ansatz zur Entwicklung von Überwachungs- und Aufklärungstechnologie ist unübertroffen und hat das Potenzial, die Art und Weise zu revolutionieren, wie Streitkräfte komplizierte und multidisziplinäre Aufklärungsmissionen bewältigen. Wir sind stolz darauf, ihre Mission in den kommenden Jahren mit autonomen UAVs in der Kampfzone zu unterstützen.”

Nachdem Russland im Februar 2022 in die Ukraine einmarschiert war, begann das in Vilnius ansässige Unternehmen Granta Autonomy mit der Lieferung seiner UAVs an die ukrainische Front. Heute betreibt die ukrainische Armee eine Batterie an UAVs von Granta Autonomy, die vom litauischen und anderen europäischen Verteidigungsministerien finanziert werden. Das Unternehmen stellt seine Technologie auch den NATO-Streitkräften in ganz Europa zur Verfügung.

Hinweise für Redaktionen:

Granta Autonomy ist ein innovatives und erfahrenes Ingenieurbüro mit Schwerpunkt auf der Entwicklung und Produktion von unbemannten Luftfahrtsystemen (UAS), Integrationen und Komponenten für Aufklärung, Überwachung, Zielerfassung und Aufklärung (ISTAR), Such- und Rettungsdienste sowie Streumunition.

Weitere Informationen finden Sie im Internet: https://www.grantaautonomy.com.

Medienkontakt: 
Nick Jones
[email protected]